156 related articles for article (PubMed ID: 37578576)
1. Diagnostic Value of MRI Features in Dual-phenotype Hepatocellular Carcinoma: A Preliminary Study.
Gu HX; Huang XS; Xu JX; Zhu P; Xu JF; Fan SF
J Digit Imaging; 2023 Dec; 36(6):2554-2566. PubMed ID: 37578576
[TBL] [Abstract][Full Text] [Related]
2. Dual-phenotype hepatocellular carcinoma: correlation of MRI features with other primary hepatocellular carcinoma and differential diagnosis.
Zhang L; Chen J; Lai X; Zhang X; Xu J
Front Oncol; 2023; 13():1253873. PubMed ID: 38273849
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Jung DH; Hwang S; Kim KH; Hong SM; Lee YJ; Ahn CS; Moon DB; Ha TY; Song GW; Park GC; Yu ES; Lee SG
World J Surg; 2017 Mar; 41(3):825-834. PubMed ID: 27812807
[TBL] [Abstract][Full Text] [Related]
4. A multivariate model based on gadoxetic acid-enhanced MRI using Li-RADS v2018 and other imaging features for preoperative prediction of dual‑phenotype hepatocellular carcinoma.
Liu MT; Zhang JY; Xu L; Qu Q; Lu MT; Jiang JF; Zhao XC; Zhang XQ; Zhang T
Radiol Med; 2023 Nov; 128(11):1333-1346. PubMed ID: 37740839
[TBL] [Abstract][Full Text] [Related]
5. Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size.
Ni T; Shang XS; Wang WT; Hu XX; Zeng MS; Rao SX
Br J Radiol; 2018 Jul; 91(1088):20180017. PubMed ID: 29791202
[TBL] [Abstract][Full Text] [Related]
6. Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.
Choi SY; Kim YK; Min JH; Kang TW; Jeong WK; Ahn S; Won H
Eur Radiol; 2018 Jun; 28(6):2549-2560. PubMed ID: 29335868
[TBL] [Abstract][Full Text] [Related]
7. Preoperative Diagnosis of Dual-Phenotype Hepatocellular Carcinoma Using Enhanced MRI Radiomics Models.
Wu Q; Yu YX; Zhang T; Zhu WJ; Fan YF; Wang XM; Hu CH
J Magn Reson Imaging; 2023 Apr; 57(4):1185-1196. PubMed ID: 36190656
[TBL] [Abstract][Full Text] [Related]
8. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study.
Ichikawa S; Isoda H; Shimizu T; Tamada D; Taura K; Togashi K; Onishi H; Motosugi U
Eur Radiol; 2020 Nov; 30(11):5992-6002. PubMed ID: 32500195
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
[TBL] [Abstract][Full Text] [Related]
10. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
[TBL] [Abstract][Full Text] [Related]
11. A multi-center diagnostic system for intrahepatic mass-forming cholangiocarcinoma based on preoperative MRI and clinical features.
Sheng R; Zhang Y; Wang H; Zhang W; Jin K; Sun W; Dai Y; Zhou J; Zeng M
Eur Radiol; 2024 Jan; 34(1):548-559. PubMed ID: 37552257
[TBL] [Abstract][Full Text] [Related]
12. [The prediction value of enhanced magnetic resonance imaging nomogram model for dual phenotype hepatocellular carcinoma].
Wu Q; Yu YX; Fan YF; Hu S; Yao FR; Wang XM; Hu CH
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(15):1086-1092. PubMed ID: 35436807
[No Abstract] [Full Text] [Related]
13. MRI for Hepatitis B-Associated Intrahepatic Cholangiocarcinoma: A Multicenter Comparative Study.
Sheng R; Wang H; Zhang Y; Sun W; Jin K; Dai Y; Zhang W; Zeng M; Zhou J
J Magn Reson Imaging; 2024 Mar; 59(3):1093-1104. PubMed ID: 37309823
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma.
Wen R; Lin P; Wu Y; Yin H; Huang W; Guo D; Peng Y; Liu D; He Y; Yang H
Eur J Radiol; 2022 Sep; 154():110415. PubMed ID: 35738166
[TBL] [Abstract][Full Text] [Related]
16. Synchronous double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma: A case report and review of the literature.
Qu MM; Zhu YH; Li YX; Li ZF; Li JK; Xu YS; Shrestha M; Lei JQ
Medicine (Baltimore); 2021 Nov; 100(46):e27349. PubMed ID: 34797273
[TBL] [Abstract][Full Text] [Related]
17. Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum.
Min JH; Kim YK; Choi SY; Jeong WK; Lee WJ; Ha SY; Ahn S; Ahn HS
Eur J Radiol; 2017 Jul; 92():1-10. PubMed ID: 28624005
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior.
Lu XY; Xi T; Lau WY; Dong H; Zhu Z; Shen F; Wu MC; Cong WM
Ann Surg Oncol; 2011 Aug; 18(8):2210-7. PubMed ID: 21308485
[TBL] [Abstract][Full Text] [Related]
19. Radiomics for diagnosis of dual-phenotype hepatocellular carcinoma using Gd-EOB-DTPA-enhanced MRI and patient prognosis.
Huang X; Long L; Wei J; Li Y; Xia Y; Zuo P; Chai X
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2995-3003. PubMed ID: 31664520
[TBL] [Abstract][Full Text] [Related]
20. The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value.
Sheng R; Yang C; Zhang Y; Wang H; Zheng B; Han J; Sun W; Zeng M
Radiol Med; 2023 Sep; 128(9):1047-1060. PubMed ID: 37474663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
